|
[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Sta-tistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Irelli, A., Sirufo, M.M., D’Ugo, C., Ginaldi, L. and De Martinis, M. (2020) Real-Life Use of Denosumab 120 mg Every 12 Weeks in Prolonged Treatment over 2 Years of Patients with Breast Cancer Bone Metastases. Journal of B.U.ON., 25, 1799-1804.
|
|
[3]
|
Tahara, R.K., Brewer, T.M., Theriault, R.L. and Ueno, N.T. (2019) Bone Metastasis of Breast Cancer. In: Ahmad, A., Eds., Breast Cancer Metastasis and Drug Resistance, Vol. 1152, Springer, Cham, 105-129. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M. and Fabbri, A. (2019) RANKL/RANK/OPG System beyond Bone Remodeling: Involvement in Breast Cancer and Clinical Perspectives. Journal of Experimental & Clinical Cancer Research, 38, Article No. 12. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Kitazawa, S. and Kitazawa, R. (2002) RANK Ligand Is a Prereq-uisite for Cancer-Associated Osteolytic Lesions. The Journal of Pathology, 198, 228-236. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Yin, J.J., Pollock, C.B. and Kelly, K. (2005) Mechanisms of Cancer Metas-tasis to the Bone. Cell Research, 15, 57-62. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Min, J.K., Kim, Y.M., Kim, Y.M., Kim, E.C., Gho, Y.S., Kang, I.J., Lee, S.Y., Kong, Y.Y. and Kwon, Y.G. (2003) Vascular Endothelial Growth Factor Up-Regulates Expression of Recep-tor Activator of NF-κB (RANK) in Endothelial Cells. Concomitant Increase of Angiogenic Responses to RANK Ligand. Journal of Biological Chemistry, 278, 39548- 39557. [Google Scholar] [CrossRef]
|
|
[8]
|
Body, J.J., Bone, H.G., De Boer, R.H., Stopeck, A., Van Poznak, C., Damiao, R., et al. (2015) Hypocalcaemia in Patients with Metastatic Bone Disease Treated with Denosumab. European Journal of Cancer, 51, 1812-1821. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Lewiecki, E.M. (2009) Denosumab Update. Current Opinion in Rheumatology, 21, 369-373. [Google Scholar] [CrossRef]
|
|
[10]
|
Yee, A.J. and Raje, N.S. (2012) Denosumab, a RANK Lig-and Inhibitor, for the Management of Bone Loss in Cancer Patients. Clinical Interventions in Aging, 7, 331-338. [Google Scholar] [CrossRef]
|
|
[11]
|
Gül, G., Sendur, M.A., Aksoy, S., Sever, A.R. and Altundag, K. (2016) A Comprehensive Review of Denosumab for Bone Metastasis in Patients with Solid Tumors. Current Medical Research and Opinion, 32, 133-145. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Gnant, M., Pfeiler, G., Steger, G.G., Egle, D., Greil, R., Fitzal, F., Wette, V., Balic, M., Haslbauer, F., Melbinger- Zeinitzer, E., Bjelic-Radisic, V., Jakesz, R., Marth, C., Sevelda, P., Mlineritsch, B., Exner, R., Fesl, C., Frantal, S., Singer, C.F. and Austrian Breast and Colorectal Cancer Study Group (2019) Adjuvant Denosumab in Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer (ABCSG-18): Disease-Free Survival Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncol-ogy, 20, 339-351. [Google Scholar] [CrossRef]
|
|
[13]
|
Zhang, C., Zhang, F., Liang, G., Zeng, X., Yu, W., Jiang, Z., et al. (2018) Denosumab versus Zoledronic Acid for Preventing Symptomatic Skeletal Events in Asian Postmenopausal Women with Oestrogen-Receptor-Positive Advanced Breast Cancer: An Outcome Analyses with a Mean Follow-Up of 3 Years. BMC Musculoskeletal Disorders, 19, Article No. 424. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Fizazi, K., Lipton, A., Mariette, X., Body, J.J., Rahim, Y., Gralow, J.R., Gao, G., Wu, L., Sohn, W. and Jun, S. (2009) Randomized Phase II Trial of Denosumab in Patients with Bone Metastases from Prostate Cancer, Breast Cancer, or Other Neoplasms after Intravenous Bisphosphonates. Journal of Clinical Oncology, 27, 1564-1571. [Google Scholar] [CrossRef]
|
|
[15]
|
O’Carrigan, B., Wong, M.H.F., Willson, M.L., Stockler, M.R., Pavlakis, N. and Goodwin, A. (2017) Bisphosphonates and Other Bone Agents for Breast Cancer. Cochrane Database of Systematic Reviews, No. 10, Article No. CD003474. [Google Scholar] [CrossRef]
|
|
[16]
|
Baron, R., Ferrari, S. and Russell, R.G. (2011) Deno-sumab and Bisphosphonates: Different Mechanisms of Action and Effects. Bone, 48, 677-692. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Lipton, A., Steger, G.G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K.S., Coleman, R., Paterson, A.H., Peterson, M.C., Fan, M., Kinsey, A. and Jun, S. (2007) Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Pa-tients with Breast Cancer-Related Bone Metastases. Journal of Clinical Oncology, 25, 4431-4437. [Google Scholar] [CrossRef]
|
|
[18]
|
Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., Fan, M., Jiang, Q., Dansey, R., Jun, S. and Braun, A. (2010) Denosumab Compared with zoledronic Acid for the Treatment of Bone Metastases in Patients with Advanced Breast Cancer: A Randomized, Double- Blind Study. Journal of Clinical Oncology, 28, 5132-5139. [Google Scholar] [CrossRef]
|